151 related articles for article (PubMed ID: 10462251)
1. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
Saul A; Lawrence G; Smillie A; Rzepczyk CM; Reed C; Taylor D; Anderson K; Stowers A; Kemp R; Allworth A; Anders RF; Brown GV; Pye D; Schoofs P; Irving DO; Dyer SL; Woodrow GC; Briggs WR; Reber R; Stürchler D
Vaccine; 1999 Aug; 17(23-24):3145-59. PubMed ID: 10462251
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
Genton B; Al-Yaman F; Anders R; Saul A; Brown G; Pye D; Irving DO; Briggs WR; Mai A; Ginny M; Adiguma T; Rare L; Giddy A; Reber-Liske R; Stuerchler D; Alpers MP
Vaccine; 2000 May; 18(23):2504-11. PubMed ID: 10775784
[TBL] [Abstract][Full Text] [Related]
3. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
Saul A; Lawrence G; Allworth A; Elliott S; Anderson K; Rzepczyk C; Martin LB; Taylor D; Eisen DP; Irving DO; Pye D; Crewther PE; Hodder AN; Murphy VJ; Anders RF
Vaccine; 2005 Apr; 23(23):3076-83. PubMed ID: 15811655
[TBL] [Abstract][Full Text] [Related]
4. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
Oliveira GA; Wetzel K; Calvo-Calle JM; Nussenzweig R; Schmidt A; Birkett A; Dubovsky F; Tierney E; Gleiter CH; Boehmer G; Luty AJ; Ramharter M; Thornton GB; Kremsner PG; Nardin EH
Infect Immun; 2005 Jun; 73(6):3587-97. PubMed ID: 15908388
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
6. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
Pierce MA; Ellis RD; Martin LB; Malkin E; Tierney E; Miura K; Fay MP; Marjason J; Elliott SL; Mullen GED; Rausch K; Zhu D; Long CA; Miller LH
Vaccine; 2010 Mar; 28(10):2236-2242. PubMed ID: 20051276
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein.
Yazdani SS; Shakri AR; Mukherjee P; Baniwal SK; Chitnis CE
Vaccine; 2004 Sep; 22(27-28):3727-37. PubMed ID: 15315853
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.
Kusi KA; Remarque EJ; Riasat V; Walraven V; Thomas AW; Faber BW; Kocken CH
Malar J; 2011 Jul; 10():182. PubMed ID: 21726452
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys.
Arévalo-Herrera M; Castellanos A; Yazdani SS; Shakri AR; Chitnis CE; Dominik R; Herrera S
Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):25-31. PubMed ID: 16291763
[TBL] [Abstract][Full Text] [Related]
13. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.
Carvalho LJ; Alves FA; Bianco C; Oliveira SG; Zanini GM; Soe S; Druilhe P; Theisen M; Muniz JA; Daniel-Ribeiro CT
Clin Diagn Lab Immunol; 2005 Feb; 12(2):242-8. PubMed ID: 15699417
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.
Roestenberg M; Remarque E; de Jonge E; Hermsen R; Blythman H; Leroy O; Imoukhuede E; Jepsen S; Ofori-Anyinam O; Faber B; Kocken CH; Arnold M; Walraven V; Teelen K; Roeffen W; de Mast Q; Ballou WR; Cohen J; Dubois MC; Ascarateil S; van der Ven A; Thomas A; Sauerwein R
PLoS One; 2008; 3(12):e3960. PubMed ID: 19093004
[TBL] [Abstract][Full Text] [Related]
15. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.
Bouillet LÉ; Dias MO; Dorigo NA; Moura AD; Russell B; Nosten F; Renia L; Braga EM; Gazzinelli RT; Rodrigues MM; Soares IS; Bruna-Romero O
Infect Immun; 2011 Sep; 79(9):3642-52. PubMed ID: 21730090
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.
McCarthy JS; Marjason J; Elliott S; Fahey P; Bang G; Malkin E; Tierney E; Aked-Hurditch H; Adda C; Cross N; Richards JS; Fowkes FJ; Boyle MJ; Long C; Druilhe P; Beeson JG; Anders RF
PLoS One; 2011; 6(9):e24413. PubMed ID: 21949716
[TBL] [Abstract][Full Text] [Related]
17. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.
Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP
PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426
[TBL] [Abstract][Full Text] [Related]
19. Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers.
Lawrence G; Cheng QQ; Reed C; Taylor D; Stowers A; Cloonan N; Rzepczyk C; Smillie A; Anderson K; Pombo D; Allworth A; Eisen D; Anders R; Saul A
Vaccine; 2000 Mar; 18(18):1925-31. PubMed ID: 10699342
[TBL] [Abstract][Full Text] [Related]
20. Long term stability of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Montanide(®) ISA 720 and stabilized with glycine.
Zhu D; McClellan H; Dai W; Gebregeorgis E; Kidwell MA; Aebig J; Rausch KM; Martin LB; Ellis RD; Miller L; Wu Y
Vaccine; 2011 May; 29(20):3640-5. PubMed ID: 21440641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
